Part 8/9:
An Uncertain Future
Biogen's strategy appears reactive rather than proactive, as it invests heavily in preclinical candidates without guaranteed revenue. Given the current market valuation, trading at a forward P/E ratio below 11, investors remain skeptical of Biogen's long-term growth prospects. Comparatively, analysts express a more favorable outlook for competitors like Celgene amidst Biogen’s decline.